CRP and rheumatoid arthritis: The rate of decrease in DAS-28 CRP scores at the 6th month of the treatment in RA and PsA patients (1.26 ± 1.28 in those with polypharmacy and 2.25 ± 1.28 in those without polypharmacy) was significantly different from the rate of decrease in their DAS-28 CRP scores at the 12th month in the treatment (1.44 ± 1.65 in those with polypharmacy, 2.64 ± 1.44 in those without) (p < 0.001 and p < 0.001).